RAPT Therapeutics (NASDAQ:RAPT) had its target price raised by investment analysts at UBS Group from $26.00 to $31.00 in a note issued to investors on Wednesday, BenzingaRatingsTable reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 24.25% from the company’s current price.
Several other equities research analysts have also commented on RAPT. BMO Capital Markets initiated coverage on shares of RAPT Therapeutics in a research note on Monday, November 25th. They issued an “outperform” rating and a $35.00 price objective for the company. Wells Fargo & Co initiated coverage on RAPT Therapeutics in a report on Monday, November 25th. They issued an “outperform” rating and a $33.00 target price for the company.
RAPT Therapeutics stock opened at $24.95 on Wednesday. RAPT Therapeutics has a fifty-two week low of $11.85 and a fifty-two week high of $42.00.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.
Further Reading: Google Finance Portfolio Workaround
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.